MSB 2.51% 97.0¢ mesoblast limited

Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-846

  1. 19 Posts.
    lightbulb Created with Sketch. 2
    Agreed. I would prefer to have the BLA submission correct and complete rather than soon. We are all impatient and invested in this process and outcome but missing the mark on the BLA due to hurrying isn't a good outcome for anyone.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.